Abiopharma

🔍 BROADWOOD PARTNERS, L.P. (Executive)

Company: STAAR SURGICAL CO (STAA)

Report Date: 2026-01-06

Detailed Transactions and Holdings:

• Acquired 186,946 shares of Common Stock at $21.0111 per share (Direct)
  Date: 2026-01-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,206,437.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 0 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,206,437.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 150,000 shares of Common Stock at $22.3756 per share (Direct)
  Date: 2026-01-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,356,437.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Acquired 0 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,356,437.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 66,467 shares of Common Stock at $22.0004 per share (Direct)
  Date: 2026-01-07 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,422,904.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Acquired 0 shares of Common Stock (Direct)
  Date: 2026-01-07 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,422,904.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,240 shares of Common Stock at $21.9389 per share (Direct)
  Date: 2026-01-08 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,426,144.00 | transaction_form_type: 4 | Footnotes: F5, F1
• Acquired 0 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: P | equity_swap_involved: 0 | shares_owned_after: 15,426,144.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: H | shares_owned_after: 25,900.00 | Footnotes: F6

Footnotes:

• F1: The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. ("Broadwood Capital") as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• F2: This constitutes the weighted average purchase price. The prices range from $20.92 to $21.09. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F3: This constitutes the weighted average purchase price. The prices range from $21.97 to $22.58. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F4: This constitutes the weighted average purchase price. The prices range from $21.81 to $22.09. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F5: This constitutes the weighted average purchase price. The prices range from $21.86 to $21.97. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F6: These securities are directly owned by Neal C. Bradsher.